Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 2/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282612 | 0.88 | SOS1 (0.47) | SOS1PTGS2PTGS1CA1CA2 | |
| SCHEMBL14959657 | 0.85 | PTGS2 (0.53) | SOS1PTGS2PTGS1 | |
| SCHEMBL1795990 | 0.80 | SOS1 (0.39) | SOS1PTGS2PTGS1PTGES2CA1 | |
| SCHEMBL1133769 | 0.76 | PGR (0.53) | SOS1PTGES2PGRCA1CA2 | |
| SCHEMBL778776 | 0.75 | PTGDR2 (0.42) | PTGS2PTGS1MAPTNPSR1KMT2A | |
| SCHEMBL283161 | 0.75 | MAOA (0.55) | SOS1TDP1MAPTKMT2AMEN1 | |
| SCHEMBL15904561 | 0.75 | HSD17B10 (0.45) | SOS1MAPTNPSR1KMT2AMEN1 | |
| SCHEMBL14959552 | 0.75 | MAOA (0.37) | SOS1PTGS2PTGS1MAPTKMT2A | |
| SCHEMBL1795988 | 0.74 | CYP1A2 (0.40) | TDP1ALDH1A1 | |
| SCHEMBL28014796 | 0.74 | NPBWR1 (0.42) | MAPTNPSR1MAOAMAOBPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2436676-A1 | Human adam-10 inhibitors | Symphony Evolution, Inc. (US) | 2012-04-04 | — | — | EP | claimed |
| US-7989661-B2 | Human ADAM-10 inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2011-08-02 | — | — | US | claimed |
| US-20100105953-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2010-04-29 | — | — | US | claimed |
| US-20060199820-A1 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | SYMPHONY EVOLUTION, INC. | 2006-09-07 | — | — | US | claimed |
| US-20250026761-A1 | DIAZABICYCLOOCTANE DERIVATIVES USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | VASA THERAPEUTICS SPÓLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (PL) | 2025-01-23 | — | — | US | disclosed |
| EP-4416153-A1 | DIAZABICYCLOOCTANE DERIVATIVES USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | Vasa Therapeutics Spolka Z Orgraniczona Odpowiedzialnoscia (PL) | 2024-08-21 | — | — | EP | disclosed |
| CN-118284611-A | Diazabicyclooctane derivatives useful as matrix metalloproteinase inhibitors | VASA治疗有限责任公司 | 2024-07-02 | — | — | CN | disclosed |
| WO-2023062492-A1 | DIAZABICYCLOOCTANE DERIVATIVES USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | VASA THERAPEUTICS SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ (PL) | 2023-04-20 | — | — | WO | disclosed |
| US-20140206865-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206865-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206865-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20130144056-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-7498358-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | EXELIXIS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498358-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | EXELIXIS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| EP-1511488-A4 | HUMAN ADAM-10 INHIBITORS | EXELIXIS INC (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20060199820-A1 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | SYMPHONY EVOLUTION, INC. | 2006-09-07 | — | — | US | disclosed |
| US-20050227973-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2005-10-13 | — | — | US | disclosed |
| EP-1511488-A2 | HUMAN ADAM-10 INHIBITORS | Exelixis, Inc. (US) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003106381-A2 | HUMAN ADAM-10 INHIBITORS | EXELIXIS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003051825-A1 | HUMAN ADAM-10 INHIBITORS | EXELIXIS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026761-A1 | DIAZABICYCLOOCTANE DERIVATIVES USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | MMP1, MMP9, MMP17 | SOS1 1310/4885PTGS2 153/4885PTGS1 116/4885 |
| US-20050227973-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, ADAM9 | SOS1 659/4885PTGS2 1827/4885PTGS1 1216/4885 |
| US-20060199820-A1 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | ADAM10, MMP20, MMP10 | SOS1 2292/4885PTGS2 297/4885PTGS1 87/4885 |
| US-20100105953-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | SOS1 1150/4885PTGS2 651/4885PTGS1 167/4885 |
| US-20140206865-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | SOS1 1150/4885PTGS2 651/4885PTGS1 167/4885 |
| US-20130144056-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | SOS1 1150/4885PTGS2 651/4885PTGS1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.